Pfizer and GlaxoSmithKline may lose contracts for supplies of vaccines to Russia

6 January 2016

Natsimbio, a subsidiary of Russia’s state corporation Rostec has signed an agreement with Serum Institute of India, one of India’s largest producers of vaccines, on the localization of production of a number of vaccines in Russia, according to an official spokesman of Rostec, reports The Pharma Letter’s local correspondent.

The project involves the launch of production of vaccines against polio, pneumococcus and Haemophilus influenzae, as well as a number of other drugs.

According to Nikolai Semyonov, chief executive of Natsimbio, production will be launched at one of the plants of the company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK